Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study

Prostate Cancer and Prostatic Diseases · Published 2025-12-26 · DOI 10.1038/s41391-025-01068-2

Authors being retrieved — see the publisher record. https://doi.org/10.1038/s41391-025-01068-2

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2025

Related articles